Table 2

Cytotoxic activity of oxovanadium (IV) compounds against leukemia (NALM-6, MOLT-3, and HL-60), Hodgkin’s lymphoma (HS445), and multiple myeloma (U266BL, ARH77, and HS-SULTAN) cells

Cells were treated with various concentrations ranging from 0.1 to 100μ m oxovanadium (IV) complexes for 48 h; cell survival was measured with MTT assays, and IC50 values were calculated with nonlinear regression analysis.

CompoundIC50m)
NALM-6MOLT-3HL-60HS445U266BLARH77HS-SULTAN
13.4 ± 0.22.7 ± 0.23.2 ± 1.16.3 ± 1.83.5 ± 0.515.6 ± 3.211.2 ± 2.2
20.97 ± 0.11.4 ± 0.044.6 ± 1.45.8 ± 1.22.2 ± 0.63.3 ± 0.84.4 ± 0.8
30.78 ± 0.11.37 ± 0.076.2 ± 2.33.3 ± 1.41.3 ± 0.18.1 ± 1.65.1 ± 1.02
40.2 ± 0.030.19 ± 0.010.98 ± 0.10.5 ± 0.080.5 ± 0.020.81 ± 0.90.8 ± 0.05
53.6 ± 0.073.4 ± 0.0315.3 ± 4.97.5 ± 2.58.5 ± 1.230.3 ± 5.69.9 ± 5.4
61.6 ± 0.032.1 ± 0.25.3 ± 1.85.2 ± 1.13.7 ± 1.110.5 ± 3.85.8 ± 0.6
74.1 ± 0.42.3 ± 0.34.9 ± 1.29.1 ± 2.518.1 ± 5.15.4 ± 1.514.5 ± 2.5
80.7 ± 0.011.4 ± 0.062.6 ± 0.42.3 ± 0.67.2 ± 1.15.7 ± 1.313.8 ± 3.6
914.9 ± 0.613.1 ± 1.1>10041.7 ± 5.430.4 ± 7.8>10062.8 ± 2.3
1015.5 ± 3.814.2 ± 3.831.4 ± 6.921.6 ± 4.332.1 ± 5.226.8 ± 5.435.4 ± 3.3
118.5 ± 0.58.2 ± 0.538.6 ± 4.527.8 ± 3.438.4 ± 3.2>10065.1 ± 6.1
123.9 ± 0.34.8 ± 0.328.4 ± 3.812.6 ± 3.313.3 ± 5.158.3 ± 6.811.4 ± 2.2
1312.1 ± 1.627.7 ± 2.5>10096.5 ± 8.691.2 ± 9.9>100>100
1412.2 ± 2.335.1 ± 4.7>10098.4 ± 9.199.1 ± 8.1>100>100
1517.4 ± 0.941.8 ± 3.9>10096.5 ± 6.498.1 ± 6.7>10078.4 ± 5.8